Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Almonty Announces Intention to Relocate to the United States (click to learn more) Benton Intersects 22.0 m Grading 7.47% Copper Including 8.0 m Grading 11.93% Copper (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Prime Medicine Inc PRME

Healthcare Biotechnology
Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering the gene editing therapies to patients. It deploys its Prime Editing platform, a gene editing technology, to develop a new class of differentiated, one-time genetic therapies. It is engaged in developing Prime Editors as a new class of therapeutics with transformative potential to expand the application of... see more

Recent & Breaking News (NDAQ:PRME)

Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 13 days ago

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Newsfile January 3, 2025

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire November 12, 2024

Prime Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire November 6, 2024

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

GlobeNewswire October 24, 2024

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

GlobeNewswire October 15, 2024

Prime Medicine Unveils Strategically Focused Pipeline

GlobeNewswire September 30, 2024

Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies

GlobeNewswire September 30, 2024

Prime Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire August 28, 2024

Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire August 8, 2024

Prime Medicine to Present at Upcoming Investor Conferences

GlobeNewswire May 30, 2024

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

GlobeNewswire May 13, 2024

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire May 10, 2024

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

GlobeNewswire May 8, 2024

Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference

GlobeNewswire May 1, 2024

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

GlobeNewswire April 29, 2024

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

GlobeNewswire April 23, 2024

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

GlobeNewswire March 1, 2024

Prime Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire February 28, 2024

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

GlobeNewswire February 20, 2024